MacroGenics logo

MacroGenicsNASDAQ: MGNX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 October 2013

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$207.75 M
-84%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
52%vs. sector
-94%vs. 3y high
32%vs. sector

Price

after hours | Thu, 21 Nov 2024 23:41:53 GMT
$3.31-$0.13(-3.78%)

Dividend

No data over the past 3 years
$110.71 M$32.55 M
$110.71 M$56.31 M

Analysts recommendations

Institutional Ownership

MGNX Latest News

MacroGenics to Participate in Upcoming Investor Conferences
globenewswire.com06 November 2024 Sentiment: POSITIVE

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript
seekingalpha.com05 November 2024 Sentiment: NEUTRAL

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Koenig - President and Chief Executive Officer Conference Call Participants Nicholas Lorusso - TD Cowen Jonathan Chang - Leerink Partners Reena Patel - Citi Etzer Darout - BMO Capital Markets Jonathan Miller - Evercore ISI Silvan Tuerkcan - Citizens JMP Securities Mayank Mamtani - B. Riley Securities Peter Lawson - Barclays Stephen Willey - Stifel Operator Good afternoon.

MacroGenics Announces Leadership Transition
globenewswire.com30 October 2024 Sentiment: NEUTRAL

ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
globenewswire.com29 October 2024 Sentiment: POSITIVE

ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders
accesswire.com25 October 2024 Sentiment: NEGATIVE

WILMINGTON, DE / ACCESSWIRE / October 25, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ GS:MGNX) on behalf of stockholders.

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
businesswire.com22 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (mar.

Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX
accesswire.com24 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104928&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX
accesswire.com24 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104874&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky
accesswire.com24 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104815&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MGNX
accesswire.com24 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=104807&wire=1 or contact Joseph E. Levi, Esq.

What type of business is MacroGenics?

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

What sector is MacroGenics in?

MacroGenics is in the Healthcare sector

What industry is MacroGenics in?

MacroGenics is in the Biotechnology industry

What country is MacroGenics from?

MacroGenics is headquartered in United States

When did MacroGenics go public?

MacroGenics initial public offering (IPO) was on 10 October 2013

What is MacroGenics website?

https://www.macrogenics.com

Is MacroGenics in the S&P 500?

No, MacroGenics is not included in the S&P 500 index

Is MacroGenics in the NASDAQ 100?

No, MacroGenics is not included in the NASDAQ 100 index

Is MacroGenics in the Dow Jones?

No, MacroGenics is not included in the Dow Jones index

When was MacroGenics the previous earnings report?

No data

When does MacroGenics earnings report?

The next expected earnings date for MacroGenics is 07 March 2025